Evaluation of liquid-crystalline nanodispersions potential functionalized with cetuximab for the incorporation of docetaxel in the treatment of prostate cancer

• Grant number: 16/22042-5
• Support Opportunities: Scholarships in Brazil - Master
• Start date: June 01, 2017
• End date: July 31, 2018
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Marlus Chorilli
• Grantee: Lucas Noboru Fatori Trevizan
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Prostate cancer is the second most common cancer among men in Brazil and it is characterized by no presenting symptoms in early stages,for this reason it is diagnosed in advanced stage, which often complicates treatment. Some related factors enhance their aggressiveness, for example, overexpression of epidermal growth factor receptor (EGFR), in some subtypes of prostate tumors. In this respect, the inhibition of the EGFR helps fight against the cancer, this function relate to the chimeric IgG1 monoclonal antibody (cetuximab) which binds to the outer portion of EGFR, inhibiting cellular proliferation, metastasis and angiogenesis and promote apoptosis. Among the forms of treatment include the brachytherapy, radiotherapy and chemotherapy using docetaxel, which has survival advantage in patients with metastatic prostate cancer resistant to antiandrogen therapy. However, the commercial formulation has side effects such as, fever, anemia, water retention, hypersensitivities, myalgia, mucositis, peripheral neuropathies, and have toxicity to skin and nails. Thus, it is appropriate to search for alternative carriers to docetaxel, as the liquid-crystalline nanodispersions, which have high characteristics of biocompatibility and the possibility of sustained release, representing a promising alternative for the delivery of this drug. In this context, the nanostructure functionalization strategies with monoclonal antibodies, such as cetuximab, also has the benefit of allowing site-specific release of the encapsulated drug, with possible reduction of side effects. It should be considered that docetaxel acts in synergism with cetuximab, justifying the combination therapy. For this reason, this proposal aims is to evaluate the potential of liquid-crystal nanodispersions functionalized with cetuximab for the placement of docetaxel in the treatment of prostate cancer, with evaluation in models of PC-3 and DU145 cell lines (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

FATORI TREVIZAN, LUCAS NOBORU; ELOY, JOSIMAR O.; LUIZ, MARCELA TAVARES; PETRILLI, RAQUEL; RAMOS JUNIOR, SERGIO LUIZ; BORGES, JULIO CESAR; MARCHETTI, JULIANA MALDONADO; CHORILLI, MARLUS. Anti-EGFR liquid crystalline nanodispersions for docetaxel delivery: Formulation, characterization and cytotoxicity in cancer cells. COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS, v. 613, MAR 20 2021. (16/22042-5)

ELOY, JOSIMAR O.; PETRILLI, RAQUEL; FATORI TREVIZAN, LUCAS NOBORU; CHORILLI, MARIUS. Immunoliposomes: A review on functionalization strategies and targets for drug delivery. COLLOIDS AND SURFACES B-BIOINTERFACES, v. 159, p. 14-pg., 2017-11-01. (17/05930-7, 16/02723-8, 16/22042-5)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

TREVIZAN, Lucas Noboru Fatori. Avaliação do potencial de nanodispersões de cristal líquido funcionalizadas com cetuximabe na veiculação de docetaxel para o tratamento do câncer de próstata. 2018. Master's Dissertation - Universidade Estadual Paulista (Unesp). Faculdade de Ciências Farmacêuticas. Araraquara Araraquara.